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Abstract: Tobacco use continues to cause 5 million preventable deaths worldwide each year.
Despite effective treatments being available, these are underutilized and cessation rates remain low.
As tobacco use has complex physiological effects, there are multiple opportunities for novel
pharmacological agents to play a role in a comprehensive treatment plan. The endocannabinoid
system has been linked to the nicotine reward pathways in animal models. Rimonabant, a selective
cannabinoid receptor (type 1) blocker, has been shown in some early clinical trials to have some
positive effects in increasing abstinence rates of smokers attempting to stop. In addition, smokers
who stop smoking with the assistance of rimonabant may gain less weight than those using
placebo. However, the results from these few trials have not been entirely consistent and so its role
as an aid to smoking cessation remains to be determined.
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Epidemiology of smoking
Tobacco use remains one of the leading causes of preventable death in the world.
Despite tobacco’s highly addictive nature, the majority of current smokers are interested
in quitting (USDHHS 2004). Even with this seeming demand for assistance with
stopping tobacco use, it is unclear how well tobacco cessation treatments are being
utilized. Over the past 20 years, various cessation medications have become available
to improve success for those smokers making a quit attempt. Currently, the United
States Food and Drug Administration (FDA) has approved 7 medications as first-line
treatments for smoking cessation (Table 1). Despite these effective products, overall
abstinence rates even with a comprehensive approach generally fall well below 40% 1 year
after the target quit-date. As novel cessation medications enter the market, clinicians
have a wider range of tools to assist smokers with their efforts, and the ability to tailor
a medication treatment plan to the individual needs of the patient.
Current pharmacotherapies for tobacco
dependence treatment
Pharmacotherapy for tobacco dependence is an important component of a
comprehensive treatment plan that includes behavioral interventions and psychosocial
support. The primary effects of nicotine are mediated by nicotinic acetylcholine
receptors, many subtypes of which are widely distributed throughout the central nervous
system. A high concentration of α4 subunits is found in the ventral tegmental area of
the brain, where a dense supply of dopamine neurons is linked to the brain’s main
“reward center,” the nucleus accumbens. An increase in extra-synaptic dopamine in
the extracellular space appears to be associated with the reinforcing and addictive
properties not only of nicotine but also of other psychostimulant drugs of abuse (eg,
amphetamine, cocaine) (Kelley 2002).Vascular Health and Risk Management 2007:3(3) 308
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The goal of using cessation medications is to reduce
cravings for tobacco and symptoms of nicotine withdrawal
that are especially severe during the first few weeks after
discontinuing tobacco use. Over the past 20 years, many
forms of cessation medications have been developed to assist
smokers in quitting (Henningfield 2005; Fagerstrom 2006).
The most commonly utilized cessation medications are
nicotine replacement medications. These agents deliver
nicotine to the brain via various routes (Table 1) in order to
replace the nicotine previously supplied by tobacco.
“Medicinal nicotine” is delivered in its safest form, as
opposed to its most dangerous form accompanied by over
4000 toxins in tobacco smoke, and binds to nicotinic
receptors in the brain, reducing cravings and withdrawal.
All of these medications have been shown to be effective at
increasing abstinence rates in clinical trials and roughly
double long-term quit rates (Hughes 1999; Fiore 2000;
Silagy 2004).
Other non-nicotine medications, such as antidepressants,
have been approved for use in smoking cessation and have
slightly different mechanisms of action (Hughes 2004).
Bupropion Sustained-Release (Zyban®, GlaxoSmithKline)
was approved for smoking cessation in 1997. This medication
inhibits reuptake of dopamine and norepinephrine in the
central nervous system, resulting in similar effects on these
neurotransmitters as caused by nicotine. In addition,
bupropion antagonizes nicotinic receptors which may reduce
the reinforcing properties of nicotine (Warner 2005).
Varenicline (Chantix
®, Pfizer) was approved in 2006 for
smoking cessation, and is a selective alpha-4-beta-2 nicotinic
acetylcholine receptor partial agonist. By this mechanism,
varenicline binds to the nicotinic receptors in the ventral
tegmental area, generating a dopamine response in the
nucleus accumbens that is lower in magnitude than that
caused by nicotine. This low-level dopamine response is less
likely to result in dependence, yet is effective in reducing
withdrawal symptoms in the absence of nicotine. In addition,
this compound acts as an antagonist at the alpha-4-beta-2
nicotinic receptor, thus reducing nicotine’s ability to bind to
the receptor and cause high-level dopamine release. Thus,
varenicline should help in reducing cravings and withdrawal
as well as reduce relapse by reducing the rewarding effects of
tobacco. In two recent clinical trials, varenicline has been
shown to improve abstinence rates over both bupropion and
placebo (Gonzales 2006; Jorenby 2006) and in another trial,
longer term use (24 weeks) was shown to reduce relapse
(Tonstad 2006).
A new mechanism of action for
cessation medications
A new class of medications has been developed affecting the
endocannabinoid system in the central nervous system. CB1
endocannabinoid receptors are found in many cell surfaces
throughout the body including brain, liver, muscle, adipose
tissue, myocardium, and others. The primary clinical effect
of these medications is to influence metabolism and energy
intake. Previous studies have demonstrated that this system
is activated by marijuana, leading to increased appetite
(Gelfand 2006). It has been hypothesized that blockade of
these receptors may be useful in weight loss, and preliminary
data suggest that medications that block endocannabinoid
receptors may have multiple beneficial clinical effects (Table 2).
Data obtained over the past 5 years have also linked the
endocannabinoid system to mechanisms of nicotine
dependence (Cohen 2005). Rimonabant is a selective CB1
receptor antagonist, and recent evidence suggests that in
addition to other clinical effects, rimonabant may also be
effective at improving abstinence among smokers. In the
central nervous system, CB1 receptors are found on GABA-
related neurons that can modulate dopamine release.
Activation of these CB1-mediated GABA neurons results in
a decrease of dopamine release. Thus, antagonism of the CB-1
receptor, such as by rimonabant, should increase dopamine
Table 1 Currently approved cessation medications
Nicotine replacement medications
Patch
Gum
Lozenge
Inhaler
Nasal spray
Non-nicotine medications
Bupropion
Varenicline
Table 2  Clinical effects of rimonabant
Decrease appetite
Weight loss
Increase HDL cholesterol (independent of weight loss effects)
Decrease triglycerides (independent of weight loss effects)
Smoking cessation
Improved glycemic control from favorable insulin action via higher
adinopectinVascular Health and Risk Management 2007:3(3) 309
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release, thought to be a major factor in the nicotine-reward
pathway.
Evidence for use of rimonabant for
smoking cessation
Animal evidence
There is evidence that the endocannabinoid system may
influence in nicotine’s reward effects in the brain. Studies of
the effects of rimonabant using animal models began in 2001,
and data have been obtained regarding the potential utility
in nicotine dependence. Cohen et al (2005) studied nicotine-
seeking behavior in rats. Rats who were given rimonabant
displayed decreased nicotine-conditioned behavior as
demonstrated by decreasing the self-administration of
nicotine and dopamine turnover in the nucleus accumbens
after nicotine stimulation. Balerio et al (2006) reported that
pretreatment with rimonabant in mice decreased the anxiety-
reducing effects of nicotine in mice who had been previously
exposed to nicotine. This study supports the link between the
endocanabanoid system and nicotine’s anxiety-like behaviors.
Clinical trial evidence
Following these animal data, clinical trials in humans began
in 2002. The trials evaluating the primary clinical effects of
rimonabant (weight loss and metabolic benefit) were
presented under the acronym RIO (Rimonabant in Obesity),
and consisted of 4 randomized studies in over 6,000 subjects
(RIO-Lipids, RIO-Europe, RIO-North America, RIO-Diabetes).
These trials demonstrated the clinical benefits of weight loss,
increased HDL cholesterol, decreased triglycerides, and
improved glucose metabolism in patients with type 2 diabetes
(Despres 2005). The most common side-effects in clinical
trials utilizing rimonabant are summarized in Table 3.
Another series of studies were designed to demonstrate
the benefit of rimonabant for smoking cessation. These were
the STRATUS (Studies with Rimonabant and Tobacco Use)
trials and they enrolled concurrently with the RIO trials. These
included two large multicenter phase III trials (STRATUS-
United States and STRATUS-Europe), and one maintenance
study (STRATUS-Worldwide). Results of these studies have
not yet been published in full, and therefore, the details
already in the public domain are summarized here.
STRATUS-US trial
The STRATUS-US trial was a randomized, three-arm (2
treatment), controlled study and enrolled 784 subjects who
smoked 10 or more cigarettes per day for at least 2 months
and were motivated to stop smoking (Dale, unpublished data;
Anthenelli 2005). Subjects were given 10 weeks of active
treatment (rimonabant) or placebo with a 42-week follow-
up. Subjects were randomly assigned to one of three treatment
conditions (rimonabant 5 mg, rimonabant 20 mg, or placebo).
The primary outcome was abstinence during weeks 7 through
10 of the follow-up. This study showed that rimonabant 20
mg roughly doubled abstinence rates compared with placebo.
The 5 mg dose had no significant effect on abstinence. In
addition, the average weight gain in the rimonabant 20 mg
group was less than 1 kg while those in the placebo group
gained just under 4 kg.
STRATUS-EU trial
The STRATUS-EU trial was a randomized, three-arm (2
treatment), controlled study with an identical protocol to the
STRATUS-US trial and enrolled 789 subjects who smoked
10 or more cigarettes per day for at least 2 months and were
motivated to stop smoking (Niaura, unpublished data).
Subjects were given 10 weeks of active treatment (rimonabant)
or placebo with a 42-week follow-up. Subjects were randomly
assigned to one of three treatment conditions (rimonabant 5
mg; rimonabant 20 mg; or placebo). The primary outcome
was abstinence during weeks 7 through 10 of the follow-up.
Abstinence rates during weeks 7 through 10 were not
statistically higher in the rimonabant arms compared with
placebo.
STRATUS worldwide
STRATUS Worldwide was a maintenance-of-abstinence trial
examining 1 year of treatment outcomes (Niaura,
unpublished data). Subjects who were abstinent at 10 weeks
Table 3  Side-effects of rimonabant
Nasopharyngitis 10–26%
Upper respiratory tract infection 8–19%
Headache 7–15%
Nausea 7–13%
Dizziness 8–10%
Back pain 7–10%
Influenza 6–10%
Anxiety 3–9%
Diarrhea 6–7%
Arthalgias 5–7%
Insomnia 4–6%
Sinusitis 3–5%
Derived from data of metabolic (Despres 2005) and smoking
cessation (Niaura 2005) trials.Vascular Health and Risk Management 2007:3(3) 310
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during the first phase of the study were re-randomized to
receive placebo, 5 mg rimonabant, or 20 mg rimonabant for
an additional 42 weeks. Those who had been on rimonabant
20 mg and were abstinent at 10 weeks were randomized to
continue on 20 mg/day, use 5 mg/day, or use placebo. Those
who had been abstinent on 5 mg/day were randomized to
continue on 5 mg/day or use placebo. Demographic and
tobacco related variables were similar among groups.
Continued abstinence was determined at 52 weeks. Higher
abstinence rates were demonstrated in those subjects
continuing on active rimonabant at either dose (20/20 mg
and 20/5 mg) compared with the 20 mg/placebo arm. The
abstinence rates were similar in the 20/20 mg and 20/5 mg
doses. Those who received the 20 mg continuation dose also
had reduction in weight gain and higher HDL cholesterol at
52 weeks. Overall adverse event rates were slightly higher in
the active arms vs. placebo, with the most frequent side-effects
reported being nausea, diarrhea, and vomiting.
Conclusions
These early studies of rimonabant have demonstrated end-
of-treatment efficacy and possibly a benefit of continuation
of therapy up to 52 weeks of treatment. In the STRATUS-US
trial, the effect size was similar to other pharmacotherapies
in roughly doubling abstinence rates, but head-to-head
comparisons with other proven medicines have not been
studied. Utilizing the endocannabinoid system offers an
additional option for treating tobacco dependence. The
possibility that rimonabant may be more efficacious in
certain subgroups of smokers is currently not known, nor is it
clear if this agent has additional benefit in combination with
other cessation medications, as has been demonstrated in
other instances (Blondal 1999; Jorenby 1999; Bohadana
2000; Steinberg 2006). It does have some potential
additional benefits compared with the currently available
pharmacotherapies including significant decreases in
weight gain at the 20 mg dose. The United States FDA
provided a decision in February 2006 that rimonabant was
“not approvable” for a smoking cessation indication. Despite
this decision, once approved for other indications, this
product may be prescribed as an “off-label” indication to help
smokers stop or to reduce weight gain during smoking
cessation. Although further evidence-based data will be
needed to fully understand the benefits and risks of this new
medication, rimonabant provides a new mechanism of action
for the treatment of tobacco dependence and for overall
reduction of cardiovascular risk.
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